1. Mibefradil Dihydrochloride
2. Posicor
3. Ro 40 5967
4. Ro 40-5967
5. Ro 405967
1. 116644-53-2
2. Mibefradil [inn:ban]
3. Ro 40-5967
4. Mibefradil (inn)
5. Mibefradil Hcl
6. [(1s,2s)-2-[2-[3-(1h-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1h-naphthalen-2-yl] 2-methoxyacetate
7. Chembl45816
8. Chebi:6920
9. 27b90x776a
10. Mibefradil [inn]
11. Acetic Acid, Methoxy-, (1s,2s)-2-[2-[[3-(1h-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl Ester
12. Acetic Acid, Methoxy-, 2-(2-((3-(1h-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl Ester, (1s-cis)-
13. Mls001056800
14. Mibefradil Dihydrochloride Hydrate
15. (1s,2s)-2-(2-((3-(1h-benzo[d]imidazol-2-yl)propyl)(methyl)amino)ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate
16. (1s,2s)-2-(2-{[3-(1h-benzimidazol-2-yl)propyl](methyl)amino}ethyl)-6-fluoro-1-(propan-2-yl)-1,2,3,4-tetrahydronaphthalen-2-yl Methoxyacetate
17. Ac1l1toe
18. Smr000326970
19. Lopac-m-5441
20. Ro 405967
21. Ro 40 5967
22. Unii-27b90x776a
23. Mibefradil [mi]
24. Mibefradil [vandf]
25. Mibefradil [who-dd]
26. Lopac0_000748
27. Schembl39551
28. (1s-cis)-2-(2-((3-(1h-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl Methoxyacetate
29. 2-(2-((3-(1h-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl Methoxyacetate (1s-cis)-
30. Mibefradildihydrochloride
31. Gtpl2522
32. Dtxsid1023318
33. Bdbm78934
34. Cid_16746591
35. Bcp09875
36. Ro40-5967
37. Zinc3782486
38. Bdbm50117922
39. Nsc760798
40. Akos022185482
41. Ccg-204833
42. Cs-1218
43. Db01388
44. Nsc-760798
45. Sdccgsbi-0050726.p002
46. Ncgc00015683-01
47. Ncgc00161420-01
48. Ncgc00161420-03
49. Ncgc00161420-04
50. Ncgc00161420-12
51. (1s,2s)-(2-((3-(2-benzimidazolyl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl Methoxyacetate
52. Hy-15553
53. Ro-405967-001
54. C07222
55. D08217
56. Q6827783
57. Brd-k09549677-300-01-8
58. (1s,2s)-2-(2-{[3-(1h-benzimidazol-2-yl)propyl](methyl)amino}ethyl)-6-fluoro-1-(1-methylethyl)-1,2,3,4-tetrahydronaphthalen-2-yl (methyloxy)acetate
59. (1s,2s)-2-[2-{[3-(1h-benzimidazol-2-yl)propyl]-methylamino }ethyl]-6-fluoro- 1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl Methoxyacetate
60. (1s,2s)-2-[2-{[3-(1h-benzimidazol-2-yl)propyl]-methylamino}ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl Methoxyacetate
61. (1s,2s)-2-[2-{[3-(1h-benzimidazol-2-yl)propyl]methylamino}ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl Methoxyacetate
62. [(1s,2s)-2-[2-[3-(1h-benzimidazol-2-yl)propyl-methyl-amino]ethyl]-6-fluoranyl-1-propan-2-yl-3,4-dihydro-1h-naphthalen-2-yl] 2-methoxyethanoate;hydrate;hydrochloride
63. [(1s,2s)-2-[2-[3-(1h-benzimidazol-2-yl)propyl-methyl-amino]ethyl]-6-fluoro-1-isopropyl-tetralin-2-yl] 2-methoxyacetate
64. [(1s,2s)-2-[2-[3-(1h-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1h-naphthalen-2-yl] 2-methoxyacetate;hydrate;hydrochloride
65. 2-{2-[3-(1h-benzoimidazol-2-yl)-propylamino]-ethyl}-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl Ester(mibefradil)methoxy-acetic Acid
66. 2-methoxyacetic Acid [(1s,2s)-2-[2-[3-(1h-benzimidazol-2-yl)propyl-methyl-amino]ethyl]-6-fluoro-1-isopropyl-tetralin-2-yl] Ester;hydrate;hydrochloride
67. 2-methoxyacetic Acid [(1s,2s)-2-[2-[3-(1h-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1h-naphthalen-2-yl] Ester;hydrate;hydrochloride
68. Methoxy-acetic Acid (1s,2s)-2-(2-{[3-(1h-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl Ester
69. Methoxy-acetic Acid 2-(2-{[3-(1h-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl Ester
| Molecular Weight | 495.6 g/mol |
|---|---|
| Molecular Formula | C29H38FN3O3 |
| XLogP3 | 5.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 12 |
| Exact Mass | 495.28972024 g/mol |
| Monoisotopic Mass | 495.28972024 g/mol |
| Topological Polar Surface Area | 67.4 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 709 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of angina and high blood pressure.
Mibefradil belongs to a group of medicines called calcium channel blocking agents, or, more commonly, calcium channel blockers. Calcium channel blocking agents affect the movement of calcium into the cells of the heart and blood vessels. As a result, they relax blood vessels and increase the supply of blood and oxygen to the heart while reducing its workload. Mibefradil is a benzimidazoyl-substituted tetraline that selectively binds and inhibits T-type calcium channels.
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
Cytochrome P-450 CYP1A2 Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inhibitors.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
C - Cardiovascular system
C08 - Calcium channel blockers
C08C - Selective calcium channel blockers with mainly vascular effects
C08CX - Other selective calcium channel blockers with mainly vascular effects
C08CX01 - Mibefradil
Absorption
Bioavailability after a single dose is 70%. After multiple dosing, the proportion of mibefradil undergoing first-pass metabolism is reduced, resulting in a steady state bioavailability of approximately 90%. Food does not affect the rate or extent of absorption of mibefradil.
The two metabolic pathways that mibefradil undergoes are esterase-catalyzed hydrolysis of the ester side chain (producing an alcohol metabolite) and cytochrome P450 3A4-catalyzed oxidation (that becomes less important during chronic dosing). The pharmacologic effect of the metabolite is approximately 10% of that of the parent mibefradil.
17 to 25 hours at steady state.
Mibefradil is a tetralol calcium channel blocking agent that inhibits the influx of calcium ions across both the T (low-voltage) and L (high-voltage) calcium channels of cardiac and vascular smooth muscle, with a greater selectivity for T channels. Vasodilation occurs in vascular smooth muscle, causing a decrease in peripheral vascular resistance and a resulting decrease in blood pressure. Mibefradil causes a slight increase in cardiac output during chronic dosing. Mibefradil slows sinus and atrioventricular (AV) node conduction, producing a slight reduction in heart rate and a slight increase in the PR interval. It has also been shown to slightly lengthen the corrected sinus node recovery time and AH interval and to raise the Wenckebach point. The mechanism by which mibefradil reduces angina is not known, but is thought to be attributed to a reduction in heart rate, total peripheral resistance (afterload), and the heart rate–systolic blood pressure product at any given level of exercise. The result of these effects is a decrease in cardiac workload and myocardial oxygen demand.
